[{"id":"3d8d662e-91a0-4d37-9933-f2e2052d2ee8","acronym":"CAPAP-lung","url":"https://clinicaltrials.gov/study/NCT04459078","created_at":"2021-01-18T21:26:31.066Z","updated_at":"2024-07-02T16:35:59.705Z","phase":"Phase 2","brief_title":"Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma","source_id_and_acronym":"NCT04459078 - CAPAP-lung","lead_sponsor":"Hunan Cancer Hospital","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" ALK mutation • EGFR negative • EGFR mutation + ALK mutation","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK mutation • EGFR negative • EGFR mutation + ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • AiTan (rivoceranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 08/26/2020","start_date":" 08/26/2020","primary_txt":" Primary completion: 05/15/2023","primary_completion_date":" 05/15/2023","study_txt":" Completion: 07/15/2023","study_completion_date":" 07/15/2023","last_update_posted":"2022-12-02"},{"id":"0de21748-af3a-488e-89cf-84c99f56357e","acronym":"SAKK 19/16","url":"https://clinicaltrials.gov/study/NCT02964689","created_at":"2021-01-18T14:34:21.117Z","updated_at":"2024-07-02T16:36:27.982Z","phase":"Phase 1","brief_title":"Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.","source_id_and_acronym":"NCT02964689 - SAKK 19/16","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" EGFR • KRAS • ALK","pipe":" | ","alterations":" EGFR mutation • ALK mutation • KRAS exon 2 mutation • EGFR mutation + ALK mutation","tags":["EGFR • KRAS • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • KRAS exon 2 mutation • EGFR mutation + ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Mektovi (binimetinib) • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 04/12/2017","start_date":" 04/12/2017","primary_txt":" Primary completion: 07/02/2021","primary_completion_date":" 07/02/2021","study_txt":" Completion: 07/02/2021","study_completion_date":" 07/02/2021","last_update_posted":"2021-07-14"},{"id":"fbf21267-ca74-47bf-abbd-ac5e09143d18","acronym":"","url":"https://clinicaltrials.gov/study/NCT04239443","created_at":"2021-01-18T20:36:54.199Z","updated_at":"2024-07-02T16:36:50.922Z","phase":"Phase 2","brief_title":"Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer","source_id_and_acronym":"NCT04239443","lead_sponsor":"Hunan Cancer Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • ALK mutation • EGFR positive • EGFR mutation + ALK mutation","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK mutation • EGFR positive • EGFR mutation + ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • AiTan (rivoceranib)"],"overall_status":"Unknown status","enrollment":" Enrollment 120","initiation":"Initiation: 01/30/2019","start_date":" 01/30/2019","primary_txt":" Primary completion: 03/31/2022","primary_completion_date":" 03/31/2022","study_txt":" Completion: 03/31/2022","study_completion_date":" 03/31/2022","last_update_posted":"2020-01-27"}]